Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831825 · ClinicalTrials.gov registry record · Phase 1
Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure
A Phase 1 study of Heart Failure With Reduced Ejection Fraction, sponsored by YAP Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06831825: Recruiting Phase 1 study of Heart Failure With Reduced Ejection Fraction, sponsored by YAP Therapeutics.
NCT06831825 is a Phase 1 study of Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by YAP Therapeutics. The registered enrollment target is 24 participants, below the 3,965-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06831825, a Phase 1 study of Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by YAP Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial investigates the safety and preliminary effectiveness of YAP101, a gene therapy designed to improve heart function in adults with ischemic heart failure and reduced ejection fraction (HFrEF). Ischemic heart failure, often resulting from a prior heart attack, leads to poor heart function and quality of life. Current treatments are limited, and there is an urgent need for new therapies. YAP101 works by delivering a gene therapy using a specialized vector to heart cells, targeting a pathway involved in heart repair. By temporarily activating heart muscle regeneration, YAP101 aims to restore damaged tissue, reduce scarring, and improve the heart's pumping ability. The study will enroll participants who will receive a one-time dose of YAP101 via a minimally invasive cardiac injection. Researchers will monitor participants over 12 months to assess safety and changes in heart function, exercise tolerance, and quality of life.
Primary Outcome
Incidence of dose limiting toxicities and adverse events
Conditions Studied
Interventions
- COMBINATION_PRODUCT YAP101 (AAV9-Sav-shRNA)
Study Locations (1)
Texas
- Texas Heart Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT06831825 shows while recruiting
NCT06831825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 3,965-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which YAP101 (AAV9-Sav-shRNA) is the first listed.
NCT06831825 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06831825 about?
NCT06831825 is a clinical study titled "Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure". This clinical trial investigates the safety and preliminary effectiveness of YAP101, a gene therapy designed to improve heart function in adults with ischemic heart failure and reduced ejection fraction (HFrEF). Ischemic heart failure, often resulting from a prior heart attack, leads to poor heart f...
What is the current status of trial NCT06831825?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-04-23. Estimated completion is 2027-06.
What conditions does trial NCT06831825 study?
This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT06831825?
The interventions under investigation include: YAP101 (AAV9-Sav-shRNA) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06831825?
This trial is sponsored by YAP Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831825 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Reduced Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06831825's enrollment target sits among peer trials
24 24th of 27 higher than 4 of 27 other Heart Failure With Reduced Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Reduced Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
COMPLETED · Phase 1
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction
RECRUITING · NA
-
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
RECRUITING
-
Study of JK07 in Patients With Chronic Heart Failure
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI